Tower Research Capital (TRC)’s GenMark Diagnostics, Inc GNMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-6,138
| Closed | -$146K | – | 6308 |
|
|
2021
Q1 | $146K | Buy |
6,138
+1,377
| +29% | +$25.6K | ﹤0.01% | 2274 |
|
|
2020
Q4 | $70K | Sell |
4,761
-60,907
| -93% | -$807K | ﹤0.01% | 2732 |
|
|
2020
Q3 | $932K | Buy |
65,668
+56,889
| +648% | +$869K | 0.01% | 1072 |
|
|
2020
Q2 | $129K | Buy |
8,779
+3,928
| +81% | +$39.9K | 0.01% | 2225 |
|
|
2020
Q1 | $20K | Buy |
+4,851
| New | +$22.7K | ﹤0.01% | 1729 |
|
|
2019
Q3 | – | Sell |
-446
| Closed | -$3K | – | 4742 |
|
|
2019
Q2 | $3K | Buy |
+446
| New | +$3.14K | ﹤0.01% | 3205 |
|
|
2019
Q1 | – | Sell |
-399
| Closed | -$2K | – | 4572 |
|
|
2018
Q4 | $2K | Sell |
399
-7,648
| -95% | -$39.8K | ﹤0.01% | 3495 |
|
|
2018
Q3 | $59K | Sell |
8,047
-1,147
| -12% | -$8.42K | ﹤0.01% | 1667 |
|
|
2018
Q2 | $59K | Buy |
+9,194
| New | +$60.8K | ﹤0.01% | 1756 |
|
|
2018
Q1 | – | Sell |
-6,659
| Closed | -$28K | – | 4104 |
|
|
2017
Q4 | $28K | Sell |
6,659
-110
| -2% | -$662 | ﹤0.01% | 1813 |
|
|
2017
Q3 | $65K | Buy |
+6,769
| New | +$70.3K | 0.01% | 1750 |
|
|
2017
Q2 | – | Sell |
-100
| Closed | -$1K | – | 3740 |
|
|
2017
Q1 | $1K | Sell |
100
-2,926
| -97% | -$35.2K | ﹤0.01% | 2900 |
|
|
2016
Q4 | $37K | Buy |
3,026
+1,547
| +105% | +$18.4K | ﹤0.01% | 1644 |
|
|
2016
Q3 | $17K | Buy |
+1,479
| New | +$14.3K | ﹤0.01% | 1729 |
|
|
2016
Q2 | – | Sell |
-265
| Closed | -$1K | – | 5223 |
|
|
2016
Q1 | $1K | Buy |
265
+236
| +814% | +$1.31K | ﹤0.01% | 3875 |
|
|
2015
Q4 | $0 | Buy |
+29
| New | +$223 | ﹤0.01% | 5299 |
|
|
2015
Q3 | – | Sell |
-2,251
| Closed | -$20K | – | 5074 |
|
|
2015
Q2 | $20K | Buy |
2,251
+1,428
| +174% | +$14.4K | ﹤0.01% | 2116 |
|
|
2015
Q1 | $11K | Sell |
823
-402
| -33% | -$5.26K | ﹤0.01% | 2730 |
|
|
2014
Q4 | $17K | Sell |
1,225
-4,492
| -79% | -$50.2K | ﹤0.01% | 1725 |
|
|
2014
Q3 | $51K | Buy |
5,717
+2,306
| +68% | +$24.8K | 0.01% | 1520 |
|
|
2014
Q2 | $46K | Buy |
3,411
+3,011
| +753% | +$31.4K | 0.01% | 1352 |
|
|
2014
Q1 | $4K | Sell |
400
-4,064
| -91% | -$50.5K | ﹤0.01% | 3496 |
|
|
2013
Q4 | $59K | Sell |
4,464
-660
| -13% | -$8.02K | 0.01% | 1257 |
|
|
2013
Q3 | $63K | Buy |
5,124
+567
| +12% | +$6.08K | 0.01% | 1712 |
|
|
2013
Q2 | $47K | Buy |
+4,557
| New | +$62.8K | ﹤0.01% | 991 |
|
Tower Research Capital (TRC)'s GNMK Position: Q2 2021 in Review
Tower Research Capital (TRC) sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 6,138 shares — an estimated $146K sold.
Tower Research Capital (TRC) first reported a position in GNMK in Q2 2013 and held it in 25 quarters. The position peaked at $932K in Q3 2020. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.
- Tower Research Capital (TRC) reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
- Tower Research Capital (TRC) sold 6,138 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $146K.
- Tower Research Capital (TRC) first reported a position in GenMark Diagnostics, Inc in Q2 2013 and held it in 25 quarters.
- Tower Research Capital (TRC)'s GenMark Diagnostics, Inc position peaked at $932K in Q3 2020.
- 0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2021, filed 16 Aug 2021.